Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction

Abstract

Methods of using inhibitors of the CD2/LFA-3 interaction-in treating skin conditions characterized by increased T cell activation and abnormal antigen presentation in the dermis and epidermis in mammals, including humans. Such conditions include psoriasis, UV damage, e.g., photoaging, atopic dermatitis, cutaneous T cell lymphoma such as mycosis fungoides, allergic and irritant contact dermatitis, lichen planus, alopecia areata, pyoderma gangrenosum, vitiligo, ocular cicatricial pemphigoid, and urticaria.

1 - 74 . (canceled)  
     
     
         75 . An anti-LFA-3 antibody, wherein the antibody is a 1E6 antibody, an HC-1B11 antibody, a 7A6 antibody, or an 8B8 antibody.  
     
     
         76 . The antibody of  claim 75 , wherein the antibody is a monoclonal antibody.  
     
     
         77 . The antibody of  claim 75 , wherein the antibody is produced by a hybridoma having an ATCC accession number selected from the group consisting of HB10693, HB 10694, HB 10695 and HB 10696.  
     
     
         78 . An anti-LFA-3 antibody having the sequence of an antibody produced by a hybridoma having an ATCC accession number selected from the group consisting of HB 10693, HB10694, HB10695 and HB10696.  
     
     
         79 . A recombinant, chimeric, or humanized antibody derived from the antibody of any one of  claims 75  to  78 .  
     
     
         80 . An antigen-binding portion of the antibody of any one of  claims 75  to  78 .  
     
     
         81 . The antigen-binding portion of  claim 80 , wherein the antigen-binding portion is an Fab fragment, an Fab′ fragment, an F(ab′) 2  fragment, an F(v) fragment, a heavy chain monomer, a heavy chain dimer, a light chain monomer, a light chain dimer, or a dimer consisting of one heavy chain and one light chain.  
     
     
         82 . An antigen-binding portion of the antibody of  claim 79 .  
     
     
         83 . The antigen-binding portion of  claim 82 , wherein the antigen-binding portion is an Fab fragment, an Fab′ fragment, an F(ab′) 2  fragment, an F(v) fragment, a heavy chain monomer, a heavy chain dimer, a light chain monomer, a light chain dimer, or a dimer consisting of one heavy chain and one light chain.